<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818036</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15010292</org_study_id>
    <nct_id>NCT02818036</nct_id>
  </id_info>
  <brief_title>An fMRI Study of Opioid-related Changes in Neural Activity</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the effect of blocking opioids on affiliation-related
      neural activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neural activity (fMRI) in response to the scanner tasks (reading sentences and viewing pictures of known and unknown people)</measure>
    <time_frame>approximately one hour after taking study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>self-reported feelings of connection (i.e. average of how connected, touched, warm did you feel) in response to the scanner tasks</measure>
    <time_frame>approximately one hour after taking study drug</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Social Acceptance</condition>
  <arm_group>
    <arm_group_label>naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 50mg dose of naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <arm_group_label>naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  good health

          -  between the ages of 18 and 35,

          -  fluent in English

          -  right-handed (for the fMRI scan)

        Exclusion Criteria:

          -  Self-reported current or past diagnoses of physical or mental illness.

          -  Score on the Patient Health Questionnaire (depressive symptoms) above a 13

          -  Positive urine drug test (for Tetrahydrocannabinol (THC), Opiates, Cocaine,
             Amphetamine (AMP), and Methamphetamine (mAMP))

          -  Positive urine pregnancy test

          -  Use of any prescription medication, except for birth control

          -  Use of any over-the-counter medications on the day of the fMRI session and 24 hours
             after the fMRI session

          -  Self-reported problems with liver functioning, including hepatitis or liver failure

          -  Difficulty swallowing or taking pills

          -  BMI greater than 35 or weight greater than 400 lbs

          -  Claustrophobia

          -  Nonremovable metal in the body
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristen Inagaki, PhD</last_name>
      <phone>412-624-4211</phone>
      <email>inagaki@pitt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Hazlett, BA</last_name>
      <email>laurahazlett@pitt.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Tristen Inagaki</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

